Klinik Araştırma

Examination of 25-Hydroxyvitamin D Levels in Patients With Benign Positional Paroxysmal Vertigo

Cilt: 7 Sayı: 3 9 Eylül 2025
PDF İndir
EN

Examination of 25-Hydroxyvitamin D Levels in Patients With Benign Positional Paroxysmal Vertigo

Abstract

Aim: Benign paroxysmal positional vertigo (BPPV) is a prevalent cause of vertigo and dizziness. This study aimed to evaluate serum 25-hydroxyvitamin D [25(OH)-D] levels in patients diagnosed with posterior canal BPPV (PCBPPV) who presented to our clinic with dizzines complaints and healty induviduals without dizzines, and to investigate the association between low serum 25(OH)-D levels and BPPV. Material and Method: Between January 2022 to March 2023, 50 patients (25 females, 25 males) with PCBPPV and 50 healthy controls (24 females, 26 males) without dizziness were enrolled. Serum 25(OH)-D levels of both groups were compared. Results: Serum 25(OH)-D levels were significantly lower in the BPPV group compared to the control group (p=0.031). Serum 25(OH)-D levels were 20ng/mL or belowin 37 patients (74%) in the patient group (mean: 14.25±3.90), while this was observed in 28 induviduals (56%) in the control group (mean: 15.94±2.19). Conclusion: Patients with BPPV exhibited significantly lower 25(OH)-D levels than healthy controls. These findings suggest that assessing vitamin D deficiency in BPPV patients may provide valuable insights into disease mechanisms and guide clinical management. Low 25(OH)-D levels appear to contribute to BPPV development.

Keywords

Etik Beyan

The study was confirmed by the Scientific Research and Publication Ethics Comission of Afyonkarahisar Health Sciences University (dated 04.10.2024, decision no. 2024/8) and the institutional permission was obtained from Afyonkarahisar State Hospital, where the research personnel are actively employed (dated 02.08.2024).

Kaynakça

  1. von Brevern M, Radtke A, Lezius F, et al. Epidemiology of benign paroxysmal positional vertigo: a population based study. J Neurol Neurosurg Psychiatry. 2007;78:710-5.
  2. Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical practice guideline: benign paroxysmal positional vertigo (update). Otolaryngol Head Neck Surg. 2017;156:S1-47.
  3. Minasyan A, Keisala T, Zou J, et al. Vestibular dysfunction in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol. 2009;114:161-6.
  4. Shigeno K, Ogita H, Funabiki K. Benign paroxysmal positional vertigo and head position during sleep. J Vestib Res. 2012;22:197-203.
  5. İnan HC, Kıraç M. An evaluation of the effects of betahistine and dimenhydrinate on posterior canal benign paroxysmal positional vertigo. Turk Arch Otorhinolaryngol. 2019;57:191-6.
  6. Motin M, Keren O, Groswasser Z, Gordon CR. Benign paroxysmal positional vertigo as the cause of dizziness in patients after severe traumatic brain injury: diagnosis and treatment. Brain Inj. 2005;19:693-7.
  7. Neuhauser HK, Lempert T. Vertigo: epidemiologic aspects. Semin Neurol. 2009;29:473-81.
  8. Parnes LS, Agrawal SK, Atlas J. Diagnosis and management of benign paroxysmal positional vertigo (BPPV). CMAJ. 2003;169:681-93.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Kulak Burun Boğaz

Bölüm

Klinik Araştırma

Yayımlanma Tarihi

9 Eylül 2025

Gönderilme Tarihi

8 Mayıs 2025

Kabul Tarihi

16 Temmuz 2025

Yayımlandığı Sayı

Yıl 2025 Cilt: 7 Sayı: 3

Kaynak Göster

AMA
1.Akçam E, Pınarbaşlı Akçam Ö. Examination of 25-Hydroxyvitamin D Levels in Patients With Benign Positional Paroxysmal Vertigo. Med Records. 2025;7(3):768-73. https://izlik.org/JA86YK25BY